Hosted on MSN
Oppenheimer Initiates Coverage of Atai Life Sciences N.V. (ATAI) with Outperform Recommendation
Fintel reports that on July 29, 2025, Oppenheimer initiated coverage of Atai Life Sciences N.V. (NasdaqGM:ATAI) with a Outperform recommendation. Analyst Price Forecast Suggests 201.20% Upside As of ...
• Apeiron and other key shareholders enter into voluntary lock-up agreements • This voluntary lock-up extends trading restrictions by 24 months for Apeiron and 12 months for other investors • ...
Hosted on MSN
ATAI stock soars on track for best day on Trump psychedelics push and Wall Street cheers
・Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares. ・Atai is now preparing for its investigational psychedelic drug ...
- atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023. - VLS-01 is a synthetic form of N,N-dimethyltryptamine (DMT) ...
NEW YORK and BERLIN - atai Life Sciences (NASDAQ:ATAI), a biopharmaceutical company focused on mental health treatments with a market capitalization of $272 million, announced significant changes to ...
ATAI Life Sciences, headquartered in Berlin, Germany, is recognized for its focus on addressing significant unmet medical needs in mental health. The company has been an emerging growth company and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results